Clinical trials: Obese Women
Overweight, Obesity
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
We are doing this study to learn more about how tirzepatide may help fight chronic kidney disease in people with obesity with or without type 2 diabetes (T2D). The study will last about 56 weeks and include up to 12 visits.
- Conditions
- Overweight, Obesity, Chronic Kidney Disease, Type 2 Diabetes
- Trial name
- TREASURE-CKD (NCT05536804)
- Testing
- Tirzepatide
- Where
- 27 sites in United States, Austria and 4 more
- Volunteers
- 134 people
- Sponsor
- Eli Lilly and Company
Healthy
A Study in Women With Overweight or Obesity to Test Whether Different Doses of BI 456906 Influence the Amount of a Contraceptive in the Blood
This study is open to women with overweight or obesity who are otherwise healthy. Women with a body mass index (BMI) from 27 to 40 kg/m2 can participate.
- Trial name
- NCT05896384
- Testing
- BI 456906, Microgynon®
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Obesity and Overweight
Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese
A phase 2 study to assess the efficacy of NA-931 alone or in addition to Tirzepatide to assess efficacy and safety in overweight or obese men and women
- Trial name
- NCT06732245
- Testing
- NA-931, Tirzepatide, NA-931 150 mg + no Tirzepatide
- Where
- 17 sites in United States, Australia and 1 more
- Volunteers
- 224 people
- Sponsor
- Biomed Industries, Inc.
Obesity
A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity
The main objective of this trial is to investigate the effect of BI 1820237 alone, BI 456906 alone, combination of BI 1820237 and BI 456906 versus placebo on brain activity.
- Trial name
- NCT06352424
- Testing
- BI 456906, BI 1820237
- Where
- Germany
- Volunteers
- 23 people
- Sponsor
- Boehringer Ingelheim
Obesity, Healthy Volunteers
Effect of Administration of Itraconazole on the Pharmacokinetics of S-309309 in Healthy Participants
The primary purpose of this study is to determine the effect of repeated administration of itraconazole on the pharmacokinetic (PK) profile of S-309309; and the PK of S-309309 following administration of S-309309 alone and…
- Trial name
- NCT06106334
- Testing
- S309309, Itraconazole
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Shionogi
Hypothalamic Obesity
A Study of Octreotide Depot vs Saline Control in Pediatric Hypothalamic Obesity Patients
The extension protocol is designed to allow those patients randomized to placebo in the core portion of the protocol to receive a 6 month treatment of open label octreotide and allow those patients randomized to octreotide who…
- Trial name
- NCT00171613
- Testing
- Octreotide
- Volunteers
- 32 people
- Sponsor
- Novartis
Overweight
A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese
The main purpose of this study is to determine the effect of LY3437943 when administered subcutaneously on the levels of combined oral contraceptive (COC) ethinyl estradiol and drospirenone in the blood stream in postmenopausal…
- Trial name
- NCT06039826
- Testing
- LY3437943, Ethinyl Estradiol, Drospirenone
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Eli Lilly and Company
Healthy Volunteers, Overweight
A Two-Part First-In-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB014295
This is a two-part, single centre, double-blind (within cohorts), randomised, placebo-controlled, single (Part 1) and multiple (Part 2) ascending subcutaneous dose study in lean to overweight or obese but otherwise healthy men…
- Trial name
- NCT06144684
- Testing
- GUB014295
- Where
- United Kingdom
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- AbbVie
Diabetes Mellitus, Type 2, Obesity
Prevalence and Overlap of Cardiovascular, Kidney, and Metabolic Diseases in Korea: A Population-based Study
This study tests the prevalence and characteristics of overlapping obesity, type 2 diabetes (T2D), cardiovascular disease (CVD), chronic kidney disease (CKD), and metabolic dysfunction-associated steatotic liver disease…
- Conditions
- Diabetes Mellitus, Type 2, Obesity, Chronic Kidney Disease, Cardiovascular Risk
- Trial name
- NCT07673822
- Testing
- No treatment given
- Where
- South Korea
- Volunteers
- 800,000 people
- Sponsor
- Novo Nordisk A/S
Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Truway Diagnostic Tools in Primary Care
This study evaluates the effectiveness of Truway Health-sourced portable diagnostic devices, including ultrasound and blood glucose monitors, in early detection of chronic conditions in outpatient primary care settings.
- Conditions
- Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight, Hypertension, Cardiovascular Disease Acute
- Trial name
- TruDxPC (NCT07209527)
- Testing
- Truway Portable Ultrasound Device, Truway Blood Glucose Monitor, Standard Oral Hypoglycemic Agent
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Truway Health, Inc.
Obesity
SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight
This study is open to women up to 65 years of age who are living with overweight or obesity and are going through or have finished menopause.
- Trial name
- NCT07850050
- Testing
- Survodutide
- Where
- 16 sites in United States, United Kingdom
- Volunteers
- 600 people
- Sponsor
- Boehringer Ingelheim
Chronic Kidney Disease
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
The study evaluates the safety of different doses of a new medicine called NNC0519 0130. It also looks into how the medicine may improve kidney function in participants with chronic kidney disease with or without type 2 diabetes…
- Trial name
- NCT06717698
- Testing
- NNC0519-0130, Semaglutide
- Where
- 147 sites in United States, Argentina and 12 more
- Volunteers
- 465 people
- Sponsor
- Novo Nordisk A/S
Obesity, Obesity, Abdominal
Immunometabolic Effects of Non-drug Strategies in the Clinical Management of Obesity: Translational Study
Forty women aged between 18 and 75 years-old with a BMI> 30kg/m2 are recruited to participate in the evaluation of their medical management.
- Conditions
- Obesity, Obesity, Abdominal, Obesity, Visceral, Female
- Trial name
- PPAR-NAPAS (NCT04436419)
- Testing
- Alpha lipoic acid (plus full hospitalization)
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Fauqué
Type 2 Diabetes, Obesity
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk.
- Conditions
- Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight
- Trial name
- ACHIEVE-4 (NCT05803421)
- Testing
- Orforglipron, Insulin Glargine
- Where
- 358 sites in United States, Argentina and 14 more
- Volunteers
- 2,749 people
- Sponsor
- Eli Lilly and Company
Healthy Participants
A Study to Investigate the Safety, Tolerability and Pharmacodynamics of AZD4144 in Participants With Obesity
The aim of this study is to evaluate the safety and tolerability, and pharmacodynamics (PD) of AZD4144 administered as repeated daily oral dosing.
- Trial name
- NCT06942923
- Testing
- AZD4144
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes, Diabetes Mellitus, Type 2
Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505
The Sponsor, Genfit, has developed a new formulation of GFT505 (60 mg). The objective is to compare the relative bioavailability between the new GFT505 formulation (capsule dosed at 60 mg GFT505) and the old GFT505 formulation…
- Conditions
- Type 2 Diabetes, Diabetes Mellitus, Type 2, Metabolic Diseases, Cardiovascular Diseases
- Trial name
- NCT01474161
- Testing
- GFT505 120mg - old formulation, GFT505 120mg - new formulation, GFT505 180mg - new formulation
- Where
- France
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Genfit
Metabolism and Nutrition Disorder, Obesity
Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity
This trial is conducted in the United States of America. The aim of this trial is to investigate Safety, Tolerability, PK (the exposure of the trial drug in the body) and PD (the effect of the investigated drug on the body) for…
- Trial name
- NCT02870231
- Testing
- NNC9204-0530, liraglutide
- Where
- 2 sites in United States
- Volunteers
- 187 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus and Heart Failure
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
This was a dose-finding study to evaluate the efficacy, safety and tolerability of 3 different doses of LIK066 compared to placebo or empagliflozin in T2DM patients with heart failure
- Trial name
- NCT03152552
- Testing
- LIK066, Empagliflozin
- Where
- 106 sites in United States, Argentina and 22 more
- Volunteers
- 125 people
- Sponsor
- Novartis Pharmaceuticals
Urinary Incontinence,Stress
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
The GZPS master protocol will support two independent studies, J2A-MC-GZS1 and J2A-MC-GZS2. Each study will see how well and safely orforglipron works in adult female participants with stress urinary incontinence (SUI) who have…
- Trial name
- RESTRAIN-SUI (NCT07202884)
- Testing
- Orforglipron
- Where
- 136 sites in United States, Canada and 8 more
- Volunteers
- 1,000 people
- Sponsor
- Eli Lilly and Company
Obesity
ERX1000 - Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Male and Female Subjects With Obesity
The primary objective is to assess the safety and tolerability of single and multiple oral doses of ERX1000 in obese subjects.
- Trial name
- NCT04890873
- Testing
- ERX1000
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- ERX Pharmaceuticals